DNA-directed DNA polymerase inhibitors, HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors)

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Acne VulgarisDiabetes Mellitus, Type 2Liver Diseases

Originator Organization

Unigen Corp.

Active Organization-

Inactive Organization

Unigen Corp.

Drug Highest PhasePendingClinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC18H24O

InChIKeyLFYJSSARVMHQJB-QIXNEVBVSA-N

CAS Registry10309-37-2

Clinical Trials associated with Drupanol

NCT03112863 / CompletedEarly Phase 1IIT

Comparison of the Cosmetic Effects of Bakuchiol and Retinol

Subjects will be assigned to a retinoid cream or bakuchiol to compare the cosmetic effects. This will take place over a 12 week period.

Start Date24 Mar 2017

Sponsor / Collaborator

University of California, Davis

ISRCTN13992386 / CompletedNot Applicable

A pilot, open-label study to evaluate the antimicrobial and anti-inflammatory properties of UP256 cream

Start Date17 Apr 2009

Sponsor / Collaborator

Unigen, Inc.

100 Clinical Results associated with Drupanol

100 Translational Medicine associated with Drupanol

100 Patents (Medical) associated with Drupanol

196

Literatures (Medical) associated with Drupanol

01 Jan 2024·Naunyn-Schmiedeberg's archives of pharmacology

Retraction Note: Assessment of anti-psoriatic activity of bakuchiol-loaded solid lipid nanoparticles-based gel: design, characterization, and mechanistic insight via NF-kB signaling pathway

Author: Tuli, Hardeep Singh ; Punj, Sanha ; Kumar, Ajay ; Kaur, Prabhjot ; Kaur, Kirandeep ; Bedi, Neena ; Attri, Shivani ; Arora, Saroj

01 Jan 2024·International journal of biological macromolecules

Bakuchiol inhibits Pseudomonas aeruginosa's quorum sensing-dependent biofilm formation by selectively inhibiting its transcriptional activator protein LasR

Article

Author: Alshehri, Fatma ; Sayed, Ahmed M ; Alasiri, Ahlam ; Soltane, Raya ; Abd El-Aleam, Rehab H ; Taha, Mostafa N

In the present study, we characterized Bakuchiol (Bak) as a new potent quorum sensing (QS) inhibitor against Pseudomonas aeruginosa biofilm formation. Upon extensive in vitro investigations, Bak was found to suppress the P. aeruginosa biofilm formation (75.5 % inhibition) and its associated virulence factor e.g., pyocyanin and rhamnolipids (% of inhibition = 71.5 % and 66.9 %, respectively). Upon LuxR-type receptors assay, Bak was found to selectively inhibit P. aeruginosa's LasR in a dose-dependent manner. Further in-depth molecular investigations (e.g., sedimentation velocity and thermal shift assays) revealed that Bak destabilized LasR upon binding and disrupted its functioning quaternary structure (i.e., the functioning dimeric form). The subsequent modeling and molecular dynamics (MD) simulations explained in more molecular detail how Bak interacts with LasR and how it can induce its dimeric form disruption. In conclusion, our study identified Bak as a potent and specific LasR antagonist that should be widely used as a chemical probe of QS in P. aeruginosa, offering new insights into LasR antagonism processes. The new findings shed light on the cryptic world of LuxR-type QS in this important opportunistic pathogen.

01 Feb 2024·The Journal of biological chemistry

Bakuchiol targets mitochondrial proteins, prohibitins and voltage-dependent anion channels: New insights into developing antiviral agents

Article

Author: Kido, Hiroshi ; Kuzuhara, Takashi ; Sato, Hinako ; Tanaka, Narue ; Masuda, Takeshi ; Takahashi, Etsuhisa ; Okamoto, Risa ; Watanabe, Mihiro ; Esumi, Tomoyuki ; Shoji, Masaki ; Ohtsuki, Sumio

We previously reported that bakuchiol, a phenolic isoprenoid anticancer compound, and its analogs exert anti-influenza activity. However, the proteins targeted by bakuchiol remain unclear. Here, we investigated the chemical structures responsible for the anti-influenza activity of bakuchiol and found that all functional groups and C6 chirality of bakuchiol were required for its anti-influenza activity. Based on these results, we synthesized a molecular probe containing a biotin tag bound to the C1 position of bakuchiol. With this probe, we performed a pulldown assay for Madin-Darby canine kidney cell lysates and purified the specific bakuchiol-binding proteins with SDS-PAGE. Using nanoLC-MS/MS analysis, we identified prohibitin (PHB) 2, voltage-dependent anion channel (VDAC) 1, and VDAC2 as binding proteins of bakuchiol. We confirmed the binding of bakuchiol to PHB1, PHB2, and VDAC2 in vitro using Western blot analysis. Immunofluorescence analysis showed that bakuchiol was bound to PHBs and VDAC2 in cells and colocalized in the mitochondria. The knockdown of PHBs or VDAC2 by transfection with specific siRNAs, along with bakuchiol cotreatment, led to significantly reduced influenza nucleoprotein expression levels and viral titers in the conditioned medium of virus-infected Madin-Darby canine kidney cells, compared to the levels observed with transfection or treatment alone. These findings indicate that reducing PHBs or VDAC2 protein, combined with bakuchiol treatment, additively suppressed the growth of influenza virus. Our findings indicate that bakuchiol exerts anti-influenza activity via a novel mechanism involving these mitochondrial proteins, providing new insight for developing anti-influenza agents.

News (Medical) associated with Drupanol

18 Jun 2024

·www.outsourcing-pharma.com

NIH awards Cellibre $2M to advance sustainable cannabinoid ingredient production

This first-of-its-kind phase 2 grant will expedite the commercialization of cannabinoid ingredient production via precision fermentation. The funding aims to develop cost-effective active pharmaceutical ingredients for treating conditions such as appetite suppression, obesity, inflammation, and diabetes. Cellibre, established in 2019 by a team of biomanufacturing innovators, is dedicated to creating a sustainable manufacturing company that utilizes biological processes as production catalysts. “Every cell on Earth functions like a tiny factory, capable of being engineered as a new way to produce chemicals and ingredients in a better, cheaper, and more sustainable way," said Cellibre CEO Ben Chiarelli. "Cellibre harnesses the world’s most elegant manufacturing technology, nature, by moving cellular assembly lines found in natural systems into microorganisms like yeast to create proprietary molecular factories. By feeding these cells nutrients, they produce pure, natural ingredients or chemicals, reducing the need to disrupt ecosystems – creating a revolution in sustainable manufacturing.” Cellibre secures $2 million NIH grant for sustainable cannabinoid production The grant will support the production of high-demand, non-euphoric cannabinoids such as tetrahydrocannabivarin (THCV) and cannabigerol (CBG). THCV is promising for appetite suppression and obesity management, while CBG is being studied for antibacterial properties and potential treatments for cancer and inflammatory diseases. Cellibre’s technology reduces cannabinoid production costs by over ten-fold compared to traditional agricultural methods. Additionally, the environmental impact of growing plants for cannabinoid production is comparable to the greenhouse gas footprint of 15 million cars annually. Cellibre’s approach significantly lowers land, water, and energy use while improving the quality and consistency of these ingredients. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Cannabinoids have significant therapeutic benefits, but manufacturing these ingredients through legacy agriculture is riddled with challenges,” said Cellibre’s Chief Technology Officer, Dr. Spiros Kambourakis. “Our precision fermentation platform solves these problems by using biology to produce high-quality, lower-cost, more sustainable cultured cannabinoids – in essence deploying nature to combat climate change, improve supply chain resilience, and improve human wellness.” Cellibre’s platforms have already shown economic and quality advantages over traditional supply chains. The award will accelerate these advances as Cellibre moves from research and development to full commercialization, focusing on therapeutically relevant cannabinoids. Precision fermentation: The future of cost-effective pharmaceutical ingredients Cellibre’s precision fermentation 'cell factory platform' drastically reduces the greenhouse gas footprint associated with agricultural and petrochemical-based supply chains for various plant-based compounds. The technology ensures a consistent, scalable supply of pharmaceutical-grade ingredients, free from the variability and impurities of agricultural-based production. Beyond cannabinoids, Cellibre’s platform also includes key bioactives for clean beauty and wellness, such as resveratrol, naringenin, bakuchiol, and other functional ingredients. “Biology is the future of manufacturing,” Kambourakis stated. “By moving production from fields to fermentation, we can create products faster, at lower costs, and with higher quality, all while protecting our natural ecosystems.” Innovative bio-manufacturing reduces environmental impact and production costs With the global cannabinoid isolate market projected to surpass $34 billion by 2030 and over 400 active clinical trials in progress, Cellibre’s technologies are crucial for ensuring patient safety and access. Cellibre is a manufacturing technology company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for large-scale production of globally significant products. The company’s scientific team has led programs from ideation to commercialization, pioneering breakthroughs in energy, ingredients, medicines, and more. Initially, Cellibre focuses on enabling the production of pharmaceutical-grade natural products and bioactives, eliminating the need for agriculture and revolutionizing the sourcing, production, and consumption of these ingredients. Cellibre was founded in 2019 and is headquartered in San Diego, California.

09 Apr 2024

·www.prnewswire.com

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

From the makers of BOTOX® Cosmetic, two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow® IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic. The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin. The two products, along with the SkinMedica® Pore Purifying Pro-Infusion Serum, used in-office with DiamondGlow®, complete the protocol, providing acne sufferers a continuum of products to help address their skin concerns. "Acne is the most common skin concern in the US.1 It is also the primary reason patients schedule an office visit with their provider.2 For 25 years, SkinMedica® has been dedicated to perfecting scientifically proven skincare that yields visible results," said Jasson Gilmore, Senior Vice President, U.S. Aesthetics. "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne." In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out. Additionally, clinical study participants noted the treatment regimen helped calm their skin.3 The SkinMedica® approach to addressing acne focuses on efficacy while respecting the skin barrier to help break the acne cycle by balancing sebum, soothing visible redness, and preserving the microbiome. "Navigating the challenges posed by acne can be difficult, and most acne products are effective at targeting acne but ignore the impact of the ingredients on the skin barrier," said Dr. Mona Gohara, board-certified dermatologist and associate clinical professor at Yale University. "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier. I am excited to offer my patients these new products from SkinMedica®, which focus on sebum regulation and barrier protection to create a desirable balance of low irritation with strong efficacy." The SkinMedica® Acne Clarifying Treatment is formulated with 2% encapsulated salicylic acid, which proactively guards against future breakouts. The product also includes ingredients like niacinamide and bakuchiol, which work together to reduce the appearance of discoloration and post-acne marks while refining pores and enhancing skin tone. With each application, this treatment becomes a shield, preserving the skin's natural barrier. MSRP $66. Complementing the Acne Clarifying Treatment is the SkinMedica® Pore Purifying Cleanser, which is infused with salicylic acid, a beta-hydroxy acid, to help remove impurities while a potent blend of antioxidants and soothing botanicals like aloe and chamomile caress the skin, leaving behind a soft and refreshed canvas. MSRP $46. The new SkinMedica® products are available for purchase at SkinMedica.com and through a network of licensed physicians and medically supervised spas. To experience the SkinMedica® Pore Purifying Pro-Infusion Serum for DiamondGlow®, find a provider by visiting DiamondGlow.com. For more information follow @SkinMedica on Instagram. About Allergan Aesthetics At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. DiamondGlow® Uses The DiamondGlow® device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic serums onto the skin. DiamondGlow® Important Safety Information The DiamondGlow® treatment is not for everyone. You should not have a DiamondGlow® treatment if you have compromised skin quality. Tell your provider if you are pregnant or lactating, or if you have any medical conditions, including allergies, and if you are using topical medications on the area to be treated. Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions. SkinMedica® Pro-Infusion Serums Disclaimer SkinMedica® Pro-Infusion Serums are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. Please talk to your provider for additional information. SkinMedica® Important Information Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. SkinMedica® Acne Clarifying Treatment is an over-the-counter drug product which is formulated and marketed pursuant to FDA's governing regulations set forth at 21 CFR Part 333 Subpart D. For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871. BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES IMPORTANT SAFETY INFORMATION BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic: Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months. Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing. BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product. There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines. BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities. Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint. Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site. Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic. Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk). Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past. Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners. Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes. Approved Uses BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults. For more information refer to the Medication Guide or talk with your doctor. To report a side effect, please call Allergan at 1-800-678-1605. Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide. References: AAD () Kline. Prograde Skincare Report. 2022.(According to Kline's Physician-Dispensed Skin Care: US Perception and Satisfaction Survey 2022, physicians noted that acne was the most common skin condition that patients visit physician's office for, followed by fine lines/wrinkles, sagging skin, and pigmentation.) Data on file at SkinMedica ® SOURCE AbbVie

02 Apr 2024

·www.prnewswire.com

Spavia Day Spa Collectively Offering $50,000 to Deserving Moms with Ultimate Luxury Spa Gift Baskets

Resort-Inspired Day Spa Celebrates Women's Wellness with Self-Care Giveaways and Systemwide Charitable Efforts to Support Deserving Moms Everywhere DENVER, April 2, 2024 /PRNewswire/ -- Spavia Day Spa, the resort-inspired day spa with 58 locations nationwide, is thrilled to announce its Mother's Day giveaway, offering guests the chance to win "Mom's Ultimate Luxury Spa Gift Basket." The giveaway, launching on World Health Day (April 7), kicks off with Spavia locations across the nation hosting open house events, setting the stage for a month-long celebration of moms and the importance of women's wellness everywhere. Continue Reading Mom’s Ultimate Luxury Spa Gift Basket Throughout the Mother's Day promotion, Spavia is igniting a movement of compassion and solidarity with concerted efforts to fundraise for local nonprofits dedicated to uplifting women and families. The goal is fostering a community where the act of celebrating your mom also becomes a beacon of hope and support for moms, women, and families in your very own neighborhood. While events vary per spa, participating locations are hosting "Mom's Ultimate Luxury Spa Gift Basket" giveaway. This golden prize giveaway is a carefully curated collection of spa and self-care essentials donated from Spavia's vendor partners and designed to help mom relax, recenter and renew. Valued at $1,000, the basket includes an array of thoughtful gifts and signature products used in Spavia's result-driven treatments, promising an unparalleled reaction from a lucky winner in each Spavia market. Collectively, the Spavia brand is expected to giveaway $50,000 worth of self-care necessities to moms nationwide. "Mom's Ultimate Luxury Spa Gift Basket" includes: Spavia Gift Card IMAGE the MAX™ Facial Cleanser IMAGE VITAL C Hydrating Facial Cleanser IMAGE Daily Prevention™ Pure Mineral Hydrating Moisturizer IMAGE White Belt-Bag Purse Lalicious Sugar Kiss Body Butter Lalicious Sugar Kiss Body Scrub Comfort Zone Luminant Serum Comfort Zone Luminant Cream Comfort Zone Tranquility Candle FarmHouse Fresh Lustre Rose FarmHouse Fresh Anti-Aging Hand Cream FarmHouse Fresh Bakuchiol Booster FarmHouse Fresh Illumination Juice Pure Fiji Orange Blossom Body Butter Pure Fiji Orange Blossom Hydrating Body Lotion Pure Fiji Nourishing Exotic Oil Scout Rose Quartz Stone of the Heart Bracelet For a chance to win "Mom's Ultimate Luxury Spa Gift Basket", guests should visit the dedicated landing page from the entry period, which is April 7- May 12, 2024. Participants will be guided to their local day spa's submission page to proceed with the nomination (limited to one submission per person). Throughout the giveaway period, community members can attend open house events to win exclusive door prizes, purchase special Mother's Day gift cards at the spa or online and explore the in-spa boutiques for curated wellness products. As a bonus and an extension of Spavia Cares, the brand and its franchise owners are supporting local charity partners with various giveback efforts that will greatly impact meaningful causes. "As a working mom myself, we believe in the power of self-care, and what better way to honor mothers than by offering them a chance to indulge in a much deserved luxurious spa experience, and continue their self-care routine with fabulous products at home," said Spavia President and Co-Founder Allison Lagenderfer. "We understand the demands of balancing work, family, and personal well-being, and it's our mission to provide a sanctuary where mothers can prioritize their self-care and rejuvenation. We're honored to see our Spavia owners supporting local charities and staying committed to bettering the lives of others every day." Spavia, a calming oasis in your backyard, invites guests to visit their neighborhood day spa and indulge in an experience like never before. Open seven days a week, Spavia provides a relaxing atmosphere and resort-inspired amenities whenever guests need it most. Guests are welcome to indulge in a variety of result-driven massage and skin care treatments, facials, body wraps, waxing, lash extensions, make-up, and more. With luxurious spa robes and sandals, a tranquil retreat area, warm aromatherapy neck pillows, inspirational readings, exotic teas, and the ability to customize every aspect of any treatment, there is something for everyone to enjoy. For more information on your local Spavia, please visit . ABOUT SPAVIA The first Spavia opened its doors in 2005 in Denver, CO, with a mission of making a positive difference in the world, one guest at a time and delivering a luxurious spa experience at an affordable price. Spavia locations provide a variety of massage treatments, skin care treatments, facials, body wraps, waxing, lash extensions, make-up, and an opportunity to celebrate with a spalebration™ — all in a relaxing and tranquil setting that allows guests to relax, recenter and renew. The 58 day spas are currently open in 23 states, reinforcing Spavia's commitment to providing affordable luxury and promoting relaxation, renewing and recentering as core values. Spavia doesn't stop at relaxation; it extends to making a positive impact. The Spavia Cares program reflects the brand's dedication to giving back to communities and helping others by contributing to fundraisers, volunteering, hosting events and providing chair massages for local events or organizations. Spavia is there to be a part of each and every community, ensuring that guests leave with a sense of fulfillment that comes from contributing to the well-being of others. SOURCE Spavia

100 Deals associated with Drupanol

External Link

KEGG	Wiki	ATC	Drug Bank
-	Drupanol	-	DB16102

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03112863 (CTgov)	Early Phase 1	Photodamaged skin	44	Bakuchiol (Bakuchiol)	qxjzejrkpw(uezfxvdpcx) = kgvmzlwvdy csumruwynn (ngyhtfrpzn, dertaghwln - aznplwefdr) View more	-	02 Nov 2021
				Retinol (Retinol)	qxjzejrkpw(uezfxvdpcx) = mkmxammkty csumruwynn (ngyhtfrpzn, dtwajqqkyl - xjtegpwqlw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis